Stock listing

Ultragenyx Pharmaceutical Inc.

Selected listing: 0LIF · LSE · USD · GB

Ultragenyx Pharmaceutical Inc. (LSE:0LIF), Health Technology. Latest release Oct 2, 2026: Ultragenyx Announces Marketing Authorisation Application (MAA)…

0LIF:LSEUSDGBUpdated October 2, 2026

Ticker: LSE:0LIF
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LSE
Currency: USD

Latest news from Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

October 1, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

October 2, 2026

Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A

September 18, 2026

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

September 17, 2026

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

September 2, 2026

All Ultragenyx Pharmaceutical Inc. news →

Events

Replays

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call
Tue, Aug 04, 2026 · 05:00 PM ET
Watch
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call
Tue, May 05, 2026 · 05:00 PM ET
Watch
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call
Thu, Feb 12, 2026 · 05:00 PM ET
Watch

Research Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. company profile

View the public company page for Ultragenyx Pharmaceutical Inc. on 6ix.

Ultragenyx Pharmaceutical Inc. news

Read company news and market updates connected to Ultragenyx Pharmaceutical Inc..

Ultragenyx Pharmaceutical Inc. investor events

Find investor webinars, events, and replay context for Ultragenyx Pharmaceutical Inc..